Marker Therapeutics (MRKR) Competitors $1.45 -0.08 (-5.23%) Closing price 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends MRKR vs. AADI, BYSI, IKNA, CLSD, MURA, FBRX, ALGS, APLT, VTVT, and GRIShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Aadi Bioscience (AADI), BeyondSpring (BYSI), Ikena Oncology (IKNA), Clearside Biomedical (CLSD), Mural Oncology (MURA), Forte Biosciences (FBRX), Aligos Therapeutics (ALGS), Applied Therapeutics (APLT), vTv Therapeutics (VTVT), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Aadi Bioscience BeyondSpring Ikena Oncology Clearside Biomedical Mural Oncology Forte Biosciences Aligos Therapeutics Applied Therapeutics vTv Therapeutics GRI Bio Marker Therapeutics (NASDAQ:MRKR) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability. Is MRKR or AADI more profitable? Marker Therapeutics has a net margin of -179.74% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% Aadi Bioscience -246.06%-71.87%-57.28% Does the media refer more to MRKR or AADI? In the previous week, Marker Therapeutics had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Marker Therapeutics and 2 mentions for Aadi Bioscience. Marker Therapeutics' average media sentiment score of 1.22 beat Aadi Bioscience's score of 0.96 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aadi Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in MRKR or AADI? Marker Therapeutics received 62 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 64.04% of users gave Marker Therapeutics an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7364.04% Underperform Votes4135.96% Aadi BioscienceOutperform Votes1139.29% Underperform Votes1760.71% Do institutionals and insiders believe in MRKR or AADI? 22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 14.5% of Marker Therapeutics shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, MRKR or AADI? Marker Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Do analysts recommend MRKR or AADI? Marker Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 1,210.34%. Aadi Bioscience has a consensus target price of $1.67, suggesting a potential downside of 27.54%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Aadi Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Aadi Bioscience 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, MRKR or AADI? Marker Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$3.31M4.69-$8.24MN/AN/AAadi Bioscience$25.07M2.27-$65.76M-$2.28-1.01 SummaryMarker Therapeutics beats Aadi Bioscience on 12 of the 17 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.53M$7.22B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E RatioN/A6.1524.9519.21Price / Sales4.69187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book0.926.447.334.28Net Income-$8.24M$139.03M$3.18B$247.04M7 Day Performance-8.23%-5.52%-4.42%-4.36%1 Month Performance-18.99%-8.56%-6.07%-5.59%1 Year Performance-60.70%-14.59%11.42%3.39% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics4.7127 of 5 stars$1.45-5.2%$19.00+1,210.3%-58.5%$15.53M$3.31M0.0060Short Interest ↓Positive NewsAADIAadi Bioscience1.2969 of 5 stars$2.72-2.5%$1.67-38.7%+33.3%$67.18M$24.35M-1.1940BYSIBeyondSpringN/A$1.72-3.9%N/A+12.7%$67.13M$1.88M0.0080Gap DownIKNAIkena Oncology2.7075 of 5 stars$1.39flat$3.00+115.8%-8.8%$67.08M$9.16M-1.1370Short Interest ↑Positive NewsCLSDClearside Biomedical3.2633 of 5 stars$0.88-7.4%$5.33+506.1%-38.2%$66.74M$7.70M-1.9630Short Interest ↓Positive NewsHigh Trading VolumeMURAMural Oncology3.3544 of 5 stars$3.86-4.7%$16.00+314.5%-31.7%$65.70MN/A-0.42119News CoverageFBRXForte Biosciences3.744 of 5 stars$10.01-8.9%$23.58+135.7%+31,340.0%$63.93MN/A-0.615Positive NewsALGSAligos Therapeutics4.0796 of 5 stars$17.73-4.8%$75.00+323.0%-40.3%$63.65M$15.53M-1.3390Short Interest ↑APLTApplied Therapeutics4.3884 of 5 stars$0.54+1.9%$6.10+1,029.6%-92.8%$62.83M$-212,000.00-0.3430VTVTvTv Therapeutics2.0368 of 5 stars$19.65-2.7%$35.00+78.2%+18.8%$62.67M$1M-4.349Analyst ForecastNews CoverageGap DownHigh Trading VolumeGRIGRI Bio2.7928 of 5 stars$6.99-0.9%$195.50+2,696.9%-95.6%$62.42MN/A0.001Gap DownHigh Trading Volume Related Companies and Tools Related Companies Aadi Bioscience Alternatives BeyondSpring Alternatives Ikena Oncology Alternatives Clearside Biomedical Alternatives Mural Oncology Alternatives Forte Biosciences Alternatives Aligos Therapeutics Alternatives Applied Therapeutics Alternatives vTv Therapeutics Alternatives GRI Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRKR) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
